Feng et al., 2021 - Google Patents
Plasma metabolomic profile associated with fatigue in cancer patientsFeng et al., 2021
View PDF- Document ID
- 4120727473608137366
- Author
- Feng L
- Barb J
- Regan J
- Saligan L
- Publication year
- Publication venue
- Cancer medicine
External Links
Snippet
Background Metabolomics is the newest‐omics methodology and allows for a functional snapshot of the biochemical activity and cellular state. The goal of this study is to characterize metabolomic profiles associated with cancer‐related fatigue, a debilitating …
- 201000011510 cancer 0 title abstract description 141
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Niu et al. | Noninvasive proteomic biomarkers for alcohol-related liver disease | |
Yu et al. | Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review | |
Feng et al. | Plasma metabolomic profile associated with fatigue in cancer patients | |
Zhang et al. | Power of metabolomics in biomarker discovery and mining mechanisms of obesity | |
Mehta et al. | Metabolomic biomarkers of pancreatic cancer: a meta-analysis study | |
Chen et al. | Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer | |
Lou et al. | Cancer-specific production of N-acetylaspartate via NAT8L overexpression in non–small cell lung cancer and its potential as a circulating biomarker | |
Unger et al. | Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma | |
Song et al. | Data‐independent acquisition‐based quantitative proteomic analysis reveals potential biomarkers of kidney cancer | |
Hsu et al. | Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma | |
Liu et al. | LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma | |
Mazzone et al. | Metabolite profiles of the serum of patients with non–small cell carcinoma | |
Tseng et al. | Identification of 14‐3‐3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker | |
Zhong et al. | Targeted high performance liquid chromatography tandem mass spectrometry-based metabolomics differentiates metabolic syndrome from obesity | |
Liang et al. | Phenotypic characterization analysis of human hepatocarcinoma by urine metabolomics approach | |
Zhang et al. | Metabolomic profiling identified serum metabolite biomarkers and related metabolic pathways of colorectal cancer | |
Zhou et al. | Metabolic detection of malignant brain gliomas through plasma lipidomic analysis and support vector machine-based machine learning | |
Kouzu et al. | Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure | |
Wang et al. | Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer | |
Voyle et al. | Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins | |
Song et al. | Screening of potential biomarkers for gastric cancer with diagnostic value using label-free global proteome analysis | |
Zhou et al. | Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure | |
Feng et al. | Steroid hormone biosynthesis metabolism is associated with fatigue related to androgen deprivation therapy for prostate cancer | |
Del Puerto‐Nevado et al. | Diabetes‐mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction | |
Zhou et al. | Prognostic biomarkers of cervical squamous cell carcinoma identified via plasma metabolomics |